Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory diseases
Biotech
Roivant’s midstage asset fails to show benefit in lung disease
Given the results, Kinevant is terminating development of the candidate—dubbed namilumab—as a potential sarcoidosis treatment.
Gabrielle Masson
Dec 3, 2024 10:32am
Jasper dials up dose after hives responses come and go quickly
Oct 14, 2024 9:43am
I&I biotech Triveni raises $115M for preclinical antibodies
Oct 2, 2024 7:00am
Sanofi makes $27M equity investment in Ventyx
Sep 23, 2024 11:24am
Inflammation-focused Upstream to join trickle of biotech IPOs
Sep 19, 2024 4:50am
Ventyx's last hope for inflammatory med ends in Crohn's failure
Jul 29, 2024 9:45am
